Physician profile
Allison Perkins
NPI 1083896047
$32,815.28
in general payments reported to CMS, 2019-2025
26 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $59.55 · 2022: $75.75 · 2023: $11K · 2024: $1,330 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Education: $6,304 · Travel and Lodging: $3,978 · Food and Beverage: $2,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,300.00 |
| Education | $6,303.75 |
| Travel and Lodging | $3,978.10 |
| Food and Beverage | $2,608.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19,053.78 | 2023-2025 | Airsupra, Breztri, Tezspire |
| Intuitive Surgical, INC. | $11,223.96 | 2023-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Veran Medical Technologies, INC. | $1,548.72 | 2019-2020 | |
| Chiesi USA, INC. | $132.01 | 2025 | |
| Ethicon INC. | $106.47 | 2025 | Monarch Platform |
| Glaxosmithkline, LLC. | $106.03 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $103.48 | 2022-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.25 | 2023-2025 | Ofev, Jascayd, Jardiance |
| Atricure, INC. | $53.41 | 2023 | |
| Genzyme Corporation | $52.72 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $44.20 | 2023 | |
| Boston Scientific Corporation | $42.43 | 2024-2025 | General - Therapies |
| Lilly USA, LLC | $34.46 | 2025 | Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $29.86 | 2025 | |
| Biosense Webster, INC. | $26.11 | 2025 | Carto 3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.02 | 2025 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $23.24 | 2023 | Dupixent |
| Verona Pharma, INC. | $21.05 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.77 | 2025 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.70 | 2023 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $17.48 | 2022 | |
| Baxter Healthcare | $16.30 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.02 | 2022 | |
| Abbvie INC. | $14.15 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $14.07 | 2023 | Arcalyst |
| Phathom Pharmaceuticals, INC. | $1.59 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.